Novartis' Multiple Sclerosis Drug Data Shows Most Patients Remain With No Disability Progression For Up To Six Years
Novartis AG (NYSE:NVS) released new data Wednesday from the ALITHIOS open-label extension study. Data show first-line ...
Novartis' Pluvicto expected to dominate prostate cancer radiopharmaceutical market
Novartis' Pluvicto is expected to dominate the market for radioligand therapies for prostate cancer, with ...
Novartis AG: Hold Rating Justified Amid Kisqali’s Market Potential and FDA Approval
Analyst Eric Le Berrigaud from Stifel Nicolaus maintained a Hold rating on Novartis AG (NOVN – Research Report) and keeping the price ...
Novartis Breast Cancer Drug Helped Delay Return of Disease
Novartis AG’s breast cancer drug helped prevent the disease coming back a year after treatment had ended, in new data that ...
Pharmabiz2d
New Novartis data in relapsing MS reinforce benefits of Kesimpta for first-line and switch patients
New Novartis data in relapsing MS reinforce benefits of Kesimpta for first-line and switch patients: Basel Friday, September 20, 2024, 12:00 Hrs [IST] Novartis announced new data ...
Business Insider4d
Maintaining Hold on Novartis: Kisqali’s Approval Meets Expectations Amid Patent Risks
In a report released yesterday, Graham Parry from Bank of America Securities maintained a Hold rating on Novartis AG (NOVN – Research Report), with a price target of CHF110.00. Graham Parry has ...
Novartis lower as BofA downgrades on risks to valuation
Novartis (NVS) stock traded lower after Bank of America downgraded the Swiss drugmaker to neutral, citing a cautious outlook ...
STAT4d
FDA awards Novartis expanded approval for breast cancer therapy
The potential market for the Novartis drug Kisqali could grow markedly, now that certain early-stage breast cancer patients ...
Novartis Breast Cancer Drug Found To Cut Disease Recurrence
Novartis said its Kisqali breast cancer drug produced longer success for those with certain forms of the disease.
Pharmaceutical Technology on MSN3d
FDA expands Novartis’ Kisqali label to include early breast cancer patients
Kisqali generated $2bn in sales last year, with broader approvals forecasting sales of over $8bn by 2030, per GlobalData ...
FiercePharma4d
Novartis heaps pressure on Lilly with broad FDA approval for Kisqali in early breast cancer
An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis and Eli Lilly in early ...